Skip to main content

Advertisement

Table 2 Results of multivariate regression analysis

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Dependent variable: Δ central systolic blood pressure Dependent variable: Δ central pulse pressure
Model 1 Beta p-value Model 2 Beta p-value Model 1 Beta p-value Model 2 Beta p-value
Sex 0.134 0.379 Sex 0.195 0.191 Sex 0.155 0.255 Sex 0.211 0.110
Age − 0.159 0.286 Age − 0.186 0.205 Age − 0.259 0.054 Age − 0.282 0.032
Δ HbA1c − 0.022 0.892 Δ Fasting plasma glucose − 0.043 0.788 Δ HbA1c 0.012 0.933 Δ Fasting plasma glucose − 0.169 0.238
Δ Copeptin 0.057 0.701 Δ Copeptin 0.054 0.710 Δ Copeptin 0.031 0.813 Δ Copeptin 0.037 0.769
Δ Hematocrit − 0.092 0.565 Δ Hematocrit − 0.096 0.556 Δ Hematocrit − 0.145 0.309 Δ Hematocrit − 0.189 0.192
Δ Heart rate 0.001 0.997 Δ Heart rate 0.043 0.787 Δ Heart rate − 0.123 0.392 Δ Heart rate − 0.056 0.686
Δ LDL-cholesterol 0.095 0.615 Δ LDL-cholesterol 0.074 0.631 Δ LDL-cholesterol − 0.126 0.365 Δ LDL-cholesterol − 0.146 0.287
Δ Uric acid − 0.083 0.642 Δ Uric acid − 0.027 0.878 Δ Uric acid − 0.124 0.438 Δ Uric acid − 0.112 0.478
Δ Systolic BP 0.412 0.018 Δ Systolic BP 0.355 0.024 Δ Systolic BP 0.364 0.019 Δ Systolic BP 0.332 0.017
Δ hsCRP 0.171 0.278 Δ hsCRP 0.192 0.231 Δ hsCRP 0.305 0.033 Δ hsCRP 0.347 0.017
  1. Model 1: Multivariate regression analysis was performed including the parameters sex, age and change of the following parameters under treatment with empagliflozin: HbA1c (model 1), copeptin concentration, hematocrit, 24-h ambulatory heart rate, LDL-cholesterol, uric acid, systolic 24-h ambulatory blood pressure and hsCRP. Model 2 included besides the other previously mentioned parameters fasting plasma glucose instead of HbA1c. LDL-cholesterol low density lipid cholesterol, hsCRP high sensitive C-reactive protein, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure, “Δ” refers to the changes due to empagliflozin treatment corrected for the placebo changes
  2. Italic values indicate significance of p-value (p < 0.05)